In a Phase II trial with metastatic melanoma patients, 103 patients were randomized to two different doses of pidizilumab, 1.5 mg/kg or 6 mg/kg given every 2 weeks for a duration of 7 months. The objective response rate reported using immune-related response criteria (irRC) was 5.9 % for the entire cohort and 10 % for the cohort receiving 1.5 mg/kg. In addition, the overall survival was 65% at 12 months. The treatment was tolerated by the patients with only 4% affected by adverse events. Moreover, it has been reported to act against diffuse large B-cell lymphoma and relapsed follicular lymphoma. However, the specificity of pidilizumab for PD-1 has been questioned and investigations are exploring this issue, hence it is still in early stage development of targeting PD-1 receptors (Festino et al.
In a Phase II trial with metastatic melanoma patients, 103 patients were randomized to two different doses of pidizilumab, 1.5 mg/kg or 6 mg/kg given every 2 weeks for a duration of 7 months. The objective response rate reported using immune-related response criteria (irRC) was 5.9 % for the entire cohort and 10 % for the cohort receiving 1.5 mg/kg. In addition, the overall survival was 65% at 12 months. The treatment was tolerated by the patients with only 4% affected by adverse events. Moreover, it has been reported to act against diffuse large B-cell lymphoma and relapsed follicular lymphoma. However, the specificity of pidilizumab for PD-1 has been questioned and investigations are exploring this issue, hence it is still in early stage development of targeting PD-1 receptors (Festino et al.